Search research articles
Contact Us
Filters
Showing results (291-300 of 418) with videos related to
Page
of 42
Sort By:
Cancer Discovery
|
December 28, 2014
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype
Kim H T Paraiso, Meghna Das Thakur, Bin Fang, et al.
Nature Communications
|
April 7, 2022
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming
Zhaowei Chu, Lei Gu, Yeguang Hu, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2011
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database
John F Thompson, Seng-Jaw Soong, Charles M Balch, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 18, 2018
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
Xin Hong, Ryan J Sullivan, Mark Kalinich, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference
Michael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.
Page
of 42
Search research articles
Search
Showing results (291-300 of 418) with videos related to
Sort By:
Page
of 42
Cancer Discovery
|
December 28, 2014
Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype
Kim H T Paraiso, Meghna Das Thakur, Bin Fang, et al.
Nature Communications
|
April 7, 2022
STAG2 regulates interferon signaling in melanoma via enhancer loop reprogramming
Zhaowei Chu, Lei Gu, Yeguang Hu, et al.
JCO Precision Oncology
|
July 10, 2024
Phase II Trial of Afatinib in Patients With <i>EGFR</i>-Mutated Solid Tumors Excluding Lung Cancer: Results From NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol A
Scott N Gettinger, Zihe Song, Karen L Reckamp, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 10, 2021
Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
Jan C Brase, Robert F H Walter, Alexander Savchenko, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 12, 2020
Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)
Douglas B Johnson, Fengmin Zhao, Marcus Noel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 27, 2011
Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database
John F Thompson, Seng-Jaw Soong, Charles M Balch, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 18, 2018
Molecular signatures of circulating melanoma cells for monitoring early response to immune checkpoint therapy
Xin Hong, Ryan J Sullivan, Mark Kalinich, et al.
The New England Journal of Medicine
|
October 2, 2012
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Keith T Flaherty, Jeffery R Infante, Adil Daud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 22, 2024
Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C
Mark H O'Hara, Opeyemi Jegede, Mark A Dickson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 27, 2007
Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference
Michael B Atkins, Marc S Ernstoff, Robert A Figlin, et al.
Page
of 42